Skip to content

Synergistic Effects and Frontal Electroencephalographic Spectral Characteristics of Remimazolam Combined With Sufentanil Sedation: A Prospective, Single-Center, Self-Controlled Pre–Post Observational Study

Synergistic Effects and Frontal Electroencephalographic Spectral Characteristics of Remimazolam Combined With Sufentanil Sedation: A Prospective, Single-Center, Self-Controlled Pre–Post Observational Study

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600119956
Enrollment
Unknown
Registered
2026-03-06
Start date
2026-03-06
Completion date
Unknown
Last updated
2026-03-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

none

Interventions

Trial group:None

Sponsors

The Second Xiangya Hospital, Central South University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 64 Years

Inclusion criteria

Inclusion criteria: 1. Age 18-64 years; 2. ASA physical status I–II; 3. BMI 18–28 kg/m²; 4. Scheduled to undergo surgery under general anesthesia with laryngeal mask airway insertion.

Exclusion criteria

Exclusion criteria: 1. Allergy to benzodiazepines; 2. Difficult airway as assessed by the anesthesiologist; 3. Previously diagnosed coronary heart disease or other cardiopulmonary insufficiency; 4. Confirmed psychiatric or neurological disorders, such as depression, anxiety, schizophrenia, or epilepsy; 5. Use of medications that may affect EEG activity, including sedative-hypnotics and/or antiepileptic drugs, within 24–48 h before surgery; 6. Abnormal liver or kidney function on laboratory testing, including total bilirubin >=3.0 mg/dL, or aspartate aminotransferase (AST) >=2.5 × the upper limit of normal, or alanine aminotransferase (ALT) =2.5 × the upper limit of normal, or renal disease (serum creatinine >=2 mg/dL); 7. Difficulty with electrode placement or persistently inadequate EEG signal quality; 8. Refusal to participate in the study.

Design outcomes

Primary

MeasureTime frame
Delta-band spectral power;vital signs;

Secondary

MeasureTime frame
Alpha-band spectral power;Alpha-band coherence;PSI values at different time points;

Countries

Chian

Contacts

Public ContactHaiding Zou

The Second Xiangya Hospital, Central South University

zhd2019@csu.edu.cn+86 150 8496 8406

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Mar 14, 2026